α9b1 integrin acts as a critical intrinsic regulator of human rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 53, Issue 3, 2014, Pages 415-424

  Asano, Tsuyoshi ^a,b   Iwasaki, Norimasa ^a   Kon, Shigeyuki ^b   Kanayama, Masashi ^b   Morimoto, Junko ^b   Minami, Akio ^a   Uede, Toshimitsu ^b  

^a Graduate School of Science   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Integrin; Osteopontin; Rheumatoid arthritis; Synovial fibroblast; Tenascin C

Indexed keywords

ALPHA9BETA1 INTEGRIN; GLYCOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOPONTIN; TENASCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE PRODUCTION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MACROPHAGE; MAJOR CLINICAL STUDY; MICROENVIRONMENT; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM;

EID: 84901698295     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket371     Document Type: Article

References (46)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
2. Arend WP. The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997;40:595-7.
3. Buckley CD. Michael Mason prize essay 2003 Why do leucocytes accumulate within chronically inflamed joints? Rheumatology 2003;42:1433-44.
4. Huber LC, Distler O, Tarner I et al. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006;45:669-75.
5. Bombara MP, Webb DL, Conrad P et al. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J Leukoc Biol 1993;54:399-406.
6. Lin YP, Su CC, Huang JY et al. Aberrant integrin activation induces p38 MAPK phosphorylation resulting in suppressed Fas-mediated apoptosis in T cells: implications for rheumatoid arthritis. Mol Immunol 2009;46:3328-35.
7. Salmon M, Scheel-Toellner D, Huissoon AP et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997;99:439-46.
8. Sarkissian M, Lafyatis R. Integrin engagement regulates proliferation and collagenase expression of rheumatoid synovial fibroblasts. J Immunol 1999;162:1772-9.
9. Wang AZ, Zhang XR, Wang JC et al. Fibronectin induces protease dependent focal matrix depletion and cell overlap in cultured rheumatoid synoviocytes. J Rheumatol 1995;22:817-28.
10. Hasegawa M, Nakoshi Y, Muraki M et al. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res 2007;25:563-8.
11. Ohshima S, Yamaguchi N, Nishioka K et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002;29:2061-7.
12. Yumoto K, Ishijima M, Rittling SR et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 2002;99:4556-61.
13. Yamamoto N, Sakai F, Kon S et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003;112:181-8.
14. Salter DM. Tenascin is increased in cartilage and synovium from arthritic knees. Br J Rheumatol 1993;32:780-6.
15. Midwood K, Sacre S, Piccinini AM et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15:774-80.
16. Chiquet-Ehrismann R. What distinguishes tenascin from fibronectin? FASEB J 1990;4:2598-604.
17. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993;7:1475-82.
18. Marcinkiewicz C, Taooka Y, Yokosaki Y et al. Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9beta 1 with VCAM-1, tenascin-C, and osteopontin. J Biol Chem 2000;275:31930-7.
19. Kanayama M, Kurotaki D, Morimoto J et al. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 2009;182:8015-25.
20. Xu G, Sun W, He D et al. Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 2005;32:410-6.
21. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.
23. Bondeson J, Wainwright SD, Lauder S et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006;8:R187.
24. Rinaldi N, Weis D, Brado B et al. Differential expression and functional behaviour of the alpha v and beta 3 integrin subunits in cytokine stimulated fibroblast-like cells derived from synovial tissue of rheumatoid arthritis and osteoarthritis in vitro. Ann Rheum Dis 1997;56:729-36.
25. Rinaldi N, Schwarz-Eywill M, Weis D et al. Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis 1997;56:45-51.
26. Yokosaki Y, Matsuura N, Higashiyama S et al. Identification of the ligand binding site for the integrin alpha9 beta1 in the third fibronectin type III repeat of tenascin-C. J Biol Chem 1998;273:11423-8.
27. Yokosaki Y, Matsuura N, Sasaki T et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999;274:36328-34.
28. Feldmann M, Brennan FM, Chantry D et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 1990;49(Suppl 1):480-6.
29. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5.
30. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
31. Palmer EL, Ruegg C, Ferrando R et al. Sequence and tissue distribution of the integrin alpha 9 subunit, a novel partner of beta 1 that is widely distributed in epithelia and muscle. J Cell Biol 1993;123:1289-97.
32. Smith LL, Cheung HK, Ling LE et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem 1996;271:28485-91.
33. Green PM, Ludbrook SB, Miller DD et al. Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett 2001;503:75-9.
34. Yamamoto N, Nakashima T, Torikai M et al. Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 2007;7:1460-70.
35. Huang XZ, Wu JF, Ferrando R et al. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol 2000;20:5208-15.
36. Shang T, Yednock T, Issekutz AC. a9b1 integrin is expressed on human neutrophils and contributes to neutrophil migration through human lung and synovial fibroblast barriers. J Leukoc Biol 1999;66:809-16.
37. Taooka Y, Chen J, Yednock T et al. The integrin a9b1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J Cell Biol 1999;145:413-20.
38. Xu G, Nie H, Li N et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 2005;115:1060-7.
39. Boumans MJ, Houbiers JG, Verschueren P et al. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 2012;71:180-5.
40. Okada Y, Nagase H, Harris ED Jr. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J Rheumatol 1987;14. Spec No:41-2.
41. Lindy O, Konttinen YT, Sorsa T et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997;40:1391-9.
42. Keyszer G, Lambiri I, Nagel R et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999;26:251-8.
43. Yamanaka H, Matsuda Y, Tanaka M et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8.
44. Hashizume M, Hayakawa N, Mihara M. IL-6 transsignalling directly induces RANKL on fibroblastlike synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology 2008;47:1635-40.
45. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factoralpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
46. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45.